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Introduction
Glyburide is the most widely used sulfonylurea drug for the 
treatment of type 2 diabetes in the United States (Riddle, 2003). 
The drug works by inhibiting ATP-sensitive K
+ (KATP) channels 
in pancreatic  cells (Ashcroft, 2005). KATP channels are octa-
meric complexes of four Kir6.x (Kir6.1 or Kir6.2) and four   
sulfonylurea receptor (SUR; SUR1 or SUR2) subunits (Clement   
et al., 1997). The SUR subunits belong to the ATP-binding cas-
sette (ABC) transporter family (Aguilar-Bryan et al., 1995) and 
function as a regulatory subunit, endowing the Kir6.x channel 
with sensitivity to inhibition by sulfonylureas such as glyburide 
and glipizide (Ashcroft, 2005). In addition to KATP channels, the 
ABC transporter ABCA1 was proposed as a putative glyburide 
target (Hamon et al., 1997). Glyburide’s pharmacological prop-
erties are summarized in Fig. S1 A.
The cystein protease caspase-1 mediates the proteolytic 
maturation of the cytokines interleukin-1 (IL-1) and IL-18   
after its recruitment in protein complexes termed inflammasomes 
(Lamkanfi and Dixit, 2009). Cryopyrin/NALP3/NLRP3 is an 
essential component of inflammasomes triggered by pathogen- 
associated molecular patterns (PAMPs), danger-associated molec-
ular patterns (DAMPs), and crystalline substances (Kanneganti   
et al., 2006, 2007; Mariathasan et al., 2006; Sutterwala et al., 2006; 
Lamkanfi and Dixit, 2009). Inappropriate Cryopyrin activity has 
been incriminated in the pathogenesis of several diseases, in-
cluding gouty arthritis, Alzheimer’s, and silicosis (Martinon   
et al., 2006; Cassel et al., 2008; Dostert et al., 2008; Halle et al., 
  I
nflammasomes  activate  caspase-1  for  processing 
and secretion of the cytokines interleukin-1 (IL-1) 
and IL-18. Cryopyrin/NALP3/NLRP3 is an essential 
component of inflammasomes triggered by microbial   
ligands, danger-associated molecular patterns (DAMPs), 
and crystals. Inappropriate Cryopyrin activity has been 
incriminated  in  the  pathogenesis  of  gouty  arthritis, 
Alzheimer’s, and silicosis. Therefore, inhibitors of the 
Nalp3  inflammasome  offer  considerable  therapeutic   
promise. In this study, we show that the type 2 diabetes 
drug glyburide prevented activation of the Cryopyrin 
inflammasome. Glyburide’s cyclohexylurea group, which 
binds  to  adenosine  triphosphatase  (ATP)–sensitive  K
+  
(KATP)  channels  for  insulin  secretion,  is  dispensable  for 
inflammasome  inhibition.  Macrophages  lacking  KATP 
subunits or ATP-binding cassette transporters also acti-
vate the Cryopyrin inflammasome normally. Glyburide 
analogues  inhibit  ATP-  but  not  hypothermia-induced 
IL-1  secretion  from  human  monocytes  expressing   
familial  cold-associated  autoinflammatory  syndrome–
associated  Cryopyrin  mutations,  thus  suggesting  that 
inhibition  occurs  upstream  of  Cryopyrin.  Concurrent 
with the role of Cryopyrin in endotoxemia, glyburide   
significantly delays lipopolysaccharide-induced lethal-
ity in mice. Therefore, glyburide is the first identified   
compound to prevent Cryopyrin activation and microbial 
ligand-, DAMP-, and crystal-induced IL-1 secretion.
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Figure 1.  Glyburide inhibits LPS+ATP-induced caspase-1 activation, secretion of IL-1 and IL-18, and macrophage cell death. (A–E) LPS-primed BMDMs 
were treated with glyburide, glipizide, or DMSO for 15 min before 5 mM ATP was added for 30 min. Cell extracts were immunoblotted for caspase-1 
(A), and culture supernatants were analyzed for secreted IL-1 (B), IL-18 (C), IL-6 (D), and TNF (E). Black arrowheads indicate procaspase-1, and white   
arrowheads mark the p20 subunit. (F) BMDMs were incubated with 200 µM glyburide, 200 µM glipizide, 200 µM DMSO, or 50 µM calmidazolium for 2 h 
before brightfield photographs were taken. (G) LPS-primed BMDMs were treated with 200 µM glyburide, glipizide, or DMSO for 15 min followed by 5 mM 
ATP for the indicated durations. Membrane damage was measured using Live/Dead assay. Bars, 20 µm. (H) BMDMs were left untreated (CTRL), stimulated   
with 10 µg/ml LPS for 3 h, treated with 5 mM ATP for 1 h, or treated with LPS and ATP. Membrane damage was measured using Live/Dead assay.   63 GLYBURIDE INHIBITS CRYOPYRIN INFLAMMASOME ACTIVATION • Lamkanfi et al.
(I) LPS-primed BMDMs from wild-type (WT), P2X7
/, Cryopyrin
/, and caspase-1
/ mice were treated with 5 mM ATP for the indicated durations. 
Membrane damage was measured with Live/Dead assay. Cytokine and cell death data represent the mean ± SD of triplicate samples from a single experi-
ment, and all results are representative of at least three independent experiments.
 
2008; Hornung et al., 2008), so inhibitors of the Cryopyrin in-
flammasome offer considerable therapeutic promise.
In this study, we show that glyburide prevented activation of 
the Cryopyrin inflammasome by a variety of stimuli. Concurrent 
with the role of Cryopyrin in endotoxemia, glyburide delayed lipo-
polysaccharide (LPS)-induced lethality in mice. Therefore, glybu-
ride is the first compound identified to act upstream of Cryopyrin 
to prevent PAMP-, DAMP-, and crystal-induced IL-1 secretion.
Results and discussion
Glyburide inhibits LPS+ATP-induced 
caspase-1 activation, IL-1 secretion,  
and macrophage death
Glyburide prevents LPS+ATP-induced secretion of IL-1 from 
human and murine macrophages (Hamon et al., 1997; Laliberte 
et al., 1999; Perregaux et al., 2001) and from murine Schwann 
cells (Marty et al., 2005). To determine whether caspase-1 acti-
vation is impaired by glyburide, LPS-primed bone marrow– 
derived macrophages (BMDMs) were incubated with glyburide 
for 15 min before ATP was added for another 30 min. In con-
trast to the related sulfonylurea glipizide, glyburide inhibited 
caspase-1 processing in a dose-dependent fashion (Fig. 1 A), 
and this prevented secretion of the caspase-1–dependent cyto-
kines IL-1 (Fig. 1 B) and IL-18 (Fig. 1 C). Secretion of IL-6 
(Fig. 1 D) and TNF (Fig. 1 E) was not impaired by glyburide, 
ruling out a general defect in macrophage responsiveness. 
Inhibition was evident up to 3 h post-ATP (Fig. S1 B), indicat-
ing that glyburide did not merely delay caspase-1 activation.
Significantly, BMDMs cultured for 3 h in glyburide, glipi-
zide, or DMSO looked morphologically normal (Fig. 1 F) and 
displayed no significant membrane damage (Fig. S1 C). As a posi-
tive control, macrophage death was induced with the calmodulin 
inhibitor calmidazolium (Fig. 1 F and Fig. S1 C). Inhibition of 
caspase-1 activation by glyburide was reversible because caspase-1 
was activated if glyburide was removed from the culture medium 
before ATP addition (Fig. S1 D). Glyburide also blocked the rapid, 
caspase-1–dependent cell death that occurs when BMDMs are 
treated with LPS and ATP (Fig. 1, G–I). As expected, glipizide 
and DMSO did not prevent this death. Of note, neither LPS nor 
ATP alone affected BMDM viability (Fig. 1 H). Like caspase-1
/ 
BMDMs, cells lacking the P2X7 receptor or Cryopyrin were not 
killed by LPS+ATP (Fig. 1 I). These results demonstrate that the   
Cryopyrin inflammasome is essential for LPS+ATP-induced   
macrophage death and that glyburide inhibits LPS+ATP-induced 
caspase-1 activation, IL-1 secretion, and macrophage death.
Glyburide’s sulfonyl and benzamido groups 
are required for optimal inhibition of the 
Cryopyrin inflammasome
Glyburide inhibits KATP channels on pancreatic  cells. Its cyclo-
hexylurea group is necessary for high affinity binding to SUR1 
(Meyer et al., 1999), which is the SUR subunit of these KATP 
channels. Interestingly, the cyclohexylurea group (Fig. 2 A, com-
pound G1) was dispensable for inhibition of LPS+ATP-induced 
caspase-1 activation (Fig. 2 B) and IL-1 secretion (Fig. 2 C). 
As expected, glyburide and compound G1 did not affect IL-6 
secretion (Fig. 2 D). Glipizide also contains a cyclohexylurea 
group (Fig. 2 A) and inhibits SUR1-containing KATP channels, 
but it failed to inhibit caspase-1 activation (Fig. 2 B). These 
data suggest that inhibition of the Cryopyrin inflammasome is 
independent of SUR1-containing KATP channels.
Additional structure activity experiments demonstrated that 
both the benzamido and sulfonyl groups of glyburide (Fig. 2 A, 
compounds  G2–G4)  were  required  for  optimal  inhibition. 
Analogue G2 comprising only the benzamido group (Fig. 2 A, 
compound G2) inhibited LPS+ATP-induced caspase-1 activa-
tion (Fig. 2 E) and IL-1 secretion (Fig. 2 F), albeit less effec-
tively than compound G1. Thus, the benzamido group contributes 
but is not sufficient for optimal inhibition. Indeed, a G1 ana-
logue lacking the benzamido group (Fig. 2 A, compound G3) 
did not affect caspase-1 activation and IL-1 secretion (Fig. 2,   
E and F). In addition to the benzamido group, the sulfonyl moi-
ety is required for optimal inhibition, as deletion of the sulfonyl 
group from compound G1 (Fig. 2 A, compound G4) was less 
effective at inhibiting caspase-1 activation and IL-1 secretion 
(Fig. 2, E and F). Like glyburide, compounds G1–G4 permitted 
normal IL-6 secretion (Fig. 2 G), demonstrating the specificity 
of these results.
Glyburide inhibits the Cryopyrin 
inflammasome downstream of the  
P2X7 receptor
Like ATP, the cation ionophore nigericin engages the Cryopyrin 
inflammasome (Mariathasan et al., 2006), but nigericin signals 
independently of the P2X7 receptor (Fig. S1, E–G; Solle et al., 
2001).  Glyburide  potently  blocked  LPS+nigericin-induced 
caspase-1 activation (Fig. 3 A). As expected, glipizide and DMSO 
vehicle did not prevent LPS+nigericin-induced caspase-1 acti-
vation. Notably, substituting lipid A, lipoteichoic acid, peptido-
glycan, or Pam3-CSK4 for LPS did not prevent glyburide from 
inhibiting caspase-1 activation (Fig. 3 B).
In agreement with previous studies (Cassel et al., 2008; 
Dostert et al., 2008; Hornung et al., 2008), silica and the lyso-
somotrophic molecule H-LL-OMe also promoted Cryopyrin-
dependent caspase-1 activation and IL-1 secretion in LPS-primed 
BMDMs (Fig. S2, A and B). Caspase-1 activation and IL-1 
secretion in response to these stimuli were independent of the 
P2X7 receptor (Fig. S2, C and D) but required TLR4 signaling 
(Fig. S2 E). Glyburide effectively blocked caspase-1 activation 
and IL-1 secretion by these stimuli too (Fig. 3, C and D). 
These data suggest that glyburide targets a signaling component 
downstream of the P2X7 receptor. We first considered the hemi-
channel pannexin-1, which was proposed to signal both LPS+ATP- 
and LPS+nigericin-induced caspase-1 activation (Pelegrin and JCB • VOLUME 187 • NUMBER 1 • 2009   64
Figure 2.  Glyburide’s cyclohexylurea moiety is dispensable for inflammasome inhibition. (A) Chemical structure of glyburide, glipizide, and glyburide-derived 
analogues G1–G4. (B–G) LPS-primed BMDMs were treated with glyburide, glipizide, or analogues G1–G4 for 15 min before 5 mM ATP was added for 
30 min. Cell extracts were immunoblotted for caspase-1 (B and E), and culture supernatants were analyzed for secreted IL-1 (C and F) and IL-6 (D and G). 
Black arrowheads indicate procaspase-1, and white arrowheads mark the p20 subunit. Cytokine data represent the mean ± SD of triplicate samples from 
a single experiment, and all results are representative of at least three independent experiments.65 GLYBURIDE INHIBITS CRYOPYRIN INFLAMMASOME ACTIVATION • Lamkanfi et al.
Figure 3.  Glyburide inhibits PAMP-, DAMP-, and crystal-induced activation of the Cryopyrin inflammasome. (A) LPS-primed BMDMs were incubated with   
200 µM glyburide, glipizide, or DMSO for 15 min before 20 µM nigericin was added for 30 min. Cell extracts were immunoblotted for caspase-1. (B) BMDMs 
were stimulated with the indicated PAMPs for 3 h, incubated with 200 µM glyburide for 15 min, and stimulated with 20 µM nigericin for 30 min. Cell extracts 
were immunoblotted for caspase-1. (C and D) LPS-primed BMDMs were incubated with 200 µM glyburide or DMSO for 15 min before 500 µg/ml silica or1 mM 
of the lysosomotrophic peptide H-LL-OMe was added for 3 h. Cell extracts were immunoblotted for caspase-1 (C), and culture supernatants were analyzed for 
secreted IL-1 (D). (E) LPS-primed BMDMs were left untreated or incubated with 200 µM glyburide or 10 µM KN-62 for 15 min. 2 µM YoPro-1 was subsequently 
added, and its uptake was visualized before and after a 5-min ATP pulse. Bars, 50 µm. (F) BMDMs were left untreated (CTRL), transfected with DOTAP alone   
for 4 h, stimulated with 10 µg/ml LPS for 3 h and subsequently with 5 mM ATP (LPS+ATP), or transfected with DOTAP and 30 µg/ml LPS for 4 h (DOTAP+LPS)   
in the presence or absence of 200 µM glyburide, glipizide, or DMSO. Cell extracts were immunoblotted for caspase-1. (G) Overview and mapping of 
inflammasome-activating stimuli and upstream signaling pathways. Black arrowheads indicate procaspase-1, and white arrowheads mark the p20 subunit. Cyto-
kine data represent the mean ± SD of triplicate samples from a single experiment, and all results are representative of at least three independent experiments.JCB • VOLUME 187 • NUMBER 1 • 2009   66
Figure 4.  KATP channels and ABC transporters are dispensable for activation of the Cryopyrin inflammasome. (A–E) BMDMs from wild-type (WT) and 
SUR2
/ (A and B), Kir6.1
/ and Kir6.2
/ (C and D), or abca1
/, abcg1
/, and abca1
//abcg1
/ (abca1/g1
/) mice (E) were left untreated 
(CTRL), stimulated with 10 µg/ml LPS for 3 h, treated with 5 mM ATP or 20 µM nigericin for 30 min, or stimulated with LPS and treated with ATP (LPS+ATP) 
or nigericin (LPS+nigericin). Cell extracts were immunoblotted for caspase-1 (A, C, and E), and culture supernatants were analyzed for secreted IL-1  
(B and D). (F–H), LPS-primed BMDMs from abca1
//abcg1
/ (F), Kir6.1
/ (G), and Kir6.2
/ (H) mice were treated with 200 µM glyburide or DMSO 
for 15 min before 5 mM ATP or 20 µM nigericin was added for an additional 30 min. Cell extracts were immunoblotted for caspase-1. Black arrowheads 
indicate procaspase-1, and white arrowheads mark the p20 subunit. Cytokine data represent the mean ± SD of triplicate samples from a single experiment, 
and all results are representative of three independent experiments.67 GLYBURIDE INHIBITS CRYOPYRIN INFLAMMASOME ACTIVATION • Lamkanfi et al.
(Mariathasan et al., 2004). Interestingly, caspase-1 activation in 
S. typhimurium–infected BMDMs was not affected by glyburide 
(Fig. 5 A). Furthermore, anthrax lethal toxin, which engages the 
NALP1b inflammasome (Boyden and Dietrich, 2006), also acti-
vated caspase-1 normally in the presence of glyburide (Fig. 5 B). 
Concurrently, glyburide did not affect caspase-1 activity in vitro 
(Fig. 5 C). These data suggest that glyburide works upstream of 
caspase-1 and ASC, the shared adaptor in the Cryopyrin, Ipaf, 
and NALP1b inflammasomes (Fig. 3 G).
We next studied the affect of glyburide and compound 
G1 on the ATPase activity of Cryopyrin, which is required for 
caspase-1 activation and IL-1 secretion (Duncan et al., 2007). 
Neither glyburide nor compound G1 reduced the ATPase activity 
of recombinant Cryopyrin (Fig. 5, D and E; and Fig. S3, C and D), 
placing glyburide action upstream of Cryopyrin. We sought 
confirmatory evidence using human peripheral blood mono-
nuclear cells (PBMCs) from individuals afflicted with familial 
cold-associated autoinflammatory syndrome (FCAS), a disorder 
resulting from a temperature-sensitive (L353P) mutation within 
Cryopyrin (Hoffman et al., 2001). Similar to LPS+ATP at 37°C, 
cold-induced conformational changes in FCAS monocytes are 
presumed to assemble the Cryopyrin inflammasome at the per-
missive temperature of 32°C. It is worth noting that FCAS mono-
cytes secreted a small amount of IL-1 at 37°C in response to either 
ATP or LPS alone (Fig. S3 E), suggesting that FCAS monocytes 
are hyperresponsive. Compound G1 inhibited LPS+ATP-induced 
IL-1 secretion at 37 and 32°C (Fig. 5 F and not depicted) but 
did not prevent cold-induced IL-1 secretion from FCAS PBMCs 
at 32°C (Fig. 5 G). Therefore, compound G1 and glyburide likely 
act upstream of Cryopyrin in inhibiting caspase-1 activation. We 
also assessed the affect of glyburide on LPS-induced lethality in 
mice based on the observation that Cryopyrin-deficient mice are 
resistant to LPS-induced lethality (Mariathasan et al., 2006; 
Sutterwala et al., 2006). Although 90% of vehicle-treated mice 
died within 20 h after LPS dosage, all mice in the glyburide-treated 
group were alive at this time point (Fig. 5 H). Mortality in the 
glyburide-treated arm was significantly delayed (P < 0.0001), but in 
line with glyburide’s relatively short half-life in vivo (1 h; unpub-
lished data), the mice eventually succumbed to endotoxic shock.
Collectively, these results demonstrate that glyburide acts 
upstream of Cryopyrin and downstream of the P2X7 receptor to 
block Cryopyrin-dependent inflammasome activation by PAMPs, 
DAMPs, and crystalline substances. These results may have 
significant therapeutic ramifications for the treatment of gouty 
arthritis, silicosis, and Alzheimer’s, in which excessive Cryo-
pyrin-dependent IL-1 production was proposed as a major 
cause of pathology (Cassel et al., 2008; Dostert et al., 2008; 
Halle et al., 2008; Hornung et al., 2008).
Materials and methods
Mice and macrophages
Cryopyrin
/,  caspase-1
/,  Abca1
/,  Abcg1
/,  Abca1
/Abcg1
/, 
Kir6.1
/, Kir6.2
/, and SUR2
/ mice have been described previously 
(Miki et al., 1998, 2002; Schott et al., 2004; Mariathasan et al., 2006; 
Stoller et al., 2007; Yvan-Charvet et al., 2008). P2X7
/ mice were ob-
tained from Lexicon Pharmaceuticals. Mice were housed in a pathogen-free 
facility. All experiments were conducted in compliance with the National   
Institutes of Health Guide for the Care and Use of Laboratory Animals and 
Surprenant, 2006, 2007; Kanneganti et al., 2007). Pannexin-1 forms 
a nonselective pore for molecules <1 kD, such as the fluorescent dye 
YoPro-1, within seconds to minutes of P2X7 receptor stimulation 
(Pelegrin and Surprenant, 2006, 2007; Locovei et al., 2007). Unlike 
the P2X7 receptor inhibitor KN-62, glyburide did not prevent ATP-
induced YoPro-1 uptake into LPS-primed macrophages (Fig. 3 E), 
suggesting that pannexin-1 is not inhibited by glyburide. Concur-
rently, glyburide inhibited caspase-1 activation by LPS+DOTAP 
(Fig. 3 F), a stimulus that engages the Cryopyrin inflammasome in-
dependently of the P2X7 receptor and pannexin-1 (Kanneganti et al., 
2007). Collectively, these results indicate that glyburide inhibits en-
gagement of the Cryopyrin inflammasome by diverse stimuli and 
that inhibition occurs downstream of the P2X7 receptor (Fig. 3 G).
KATP channels and ABC transporters  
are dispensable for activation of the 
Cryopyrin inflammasome
The structure–activity relationship experiments (Fig. 2) suggest 
that glyburide inhibits the Cryopyrin inflammasome indepen-
dently of SUR1-containing KATP channels. Certain tissues such 
as heart and muscle express SUR2 instead of SUR1 KATP chan-
nels. However, SUR2
/ BMDMs activated caspase-1 and se-
creted normal amounts of IL-1 in response to LPS+ATP and 
LPS+nigericin (Fig. 4, A and B). In addition, BMDMs from 
Kir6.1
/ and Kir6.2
/ mice also demonstrated normal LPS+ATP- 
and LPS+nigericin-induced caspase-1 activation (Fig. 4 C) and 
IL-1 secretion (Fig. 4 D). These results show that KATP channels 
are not required for activation of the Cryopyrin inflammasome.
Previous studies also suggested that glyburide and the ABC 
transporter inhibitor DIDS (4,4-diisothiocyanatostilbene-2,2- 
disulfonic acid disodium) target ABCA1 to inhibit LPS+ATP-
induced  IL-1  secretion  (Hamon  et  al.,  1997;  Marty  et  al., 
2005). We confirmed that DIDS inhibited LPS+ATP-induced   
IL-1 secretion in a dose-dependent manner (Fig. S3 A). How-
ever, DIDS also inhibited P2X7 receptor-mediated currents   
(Ma et al., 2009) and caspase-1 activation (Fig. S3 B), suggesting 
that the drug prevents IL-1 secretion by directly antagonizing 
the P2X7 receptor rather than ABCA1. Concurrently, BMDMs 
from mice lacking ABCA1 and/or ABCG1 activated caspase-1 
normally in response to LPS+ATP and LPS+nigericin (Fig. 4 E). 
Caspase-1 activation also was normal in macrophages lacking 
the glyburide receptor cystic fibrosis transmembrane conduc-
tance regulator (unpublished data).
To complement these experiments, we analyzed whether 
glyburide prevented caspase-1 activation in macrophages lacking 
ABC transporters or KATP channels. As in wild-type macrophages 
(Fig. 1 A), glyburide abolished LPS+ATP- and LPS+nigericin-
induced caspase-1 activation in macrophages lacking ABCA1 and 
ABCG1 (Fig. 4 F) or the KATP channel subunits Kir6.1 (Fig. 4 G) 
and Kir6.2 (Fig. 4 H). In summary, these experiments indicate 
that known targets of glyburide are dispensable for activation of 
the Cryopyrin inflammasome.
Inflammasome inhibition occurs upstream 
of Cryopyrin
Ipaf rather than Cryopyrin is critical for inflammasome assembly 
and caspase-1 activation by Salmonella typhimurium infection JCB • VOLUME 187 • NUMBER 1 • 2009   68
Figure 5.  Glyburide inhibits the inflammasome upstream of Cryopyrin. (A and B) BMDMs from C57BL/6 (A) or BALB/c mice (B) were stimulated with   
10 µg/ml LPS for 3 h and treated with 5 mM ATP for 30 min (LPS+ATP), infected with S. typhimurium for 4 h, or treated with 10 µg/ml anthrax lethal toxin 
(PA+LF) for 4 h in the presence or absence of 200 µM glyburide. Cell extracts were immunoblotted for caspase-1. Black arrowheads indicate procaspase-1, 
and white arrowheads mark the p20 subunit. (C) In vitro enzymatic activity of 1 IU mouse caspase-1 incubated with glyburide, glipizide, or the caspase-1 
inhibitor Ac-YVAD-cmk. Data represent the mean ± SD of triplicate samples from one out of three independent experiments. (D and E) ATPase activity of 
purified recombinant Cryopyrin and control eluates in the presence of 100 µM glyburide, compound G1, or glipizide (D). (E) ATPase activity quantified by 69 GLYBURIDE INHIBITS CRYOPYRIN INFLAMMASOME ACTIVATION • Lamkanfi et al.
Photoshop (Adobe). Macrophage membrane damage was measured with 
a Live/Dead assay (Invitrogen).
Cytokines, antibodies, and Western blotting
Human and mouse cytokines in culture supernatants were measured by 
enzyme-linked immunoabsorbent assay (R&D Systems) and Luminex assay. 
Data were analyzed with Student’s t test, and P < 0.05 was considered 
statistically significant. The caspase-1 antibody used for Western blotting 
was raised against recombinant mouse caspase-1 and was used as de-
scribed previously (Lamkanfi et al., 2007). In brief, immunoblots were incu-
bated overnight with the caspase-1 antibody (1:1,000), and a goat 
anti–rabbit secondary antibody (Jackson ImmunoResearch Laboratories, 
Inc.) was used to detect proteins by enhanced chemiluminescence (Thermo 
Fisher Scientific).
In vitro caspase-1 activity assay
In vitro caspase-1 activity was determined by incubating 1 IU recombi-
nant  mouse  caspase-1  (BioVision)  with  50  mM  fluorogenic  caspase-1 
substrate peptide Ac-WEHD-amc in 200 ml CFS buffer (10 mM Hepes,   
pH 7.4, 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM KH2PO4,   
0.5 mM EGTA, 2 mM MgCl2, 0.5 mM sodium pyruvate, 0.5 mM L-glutamine, 
and 10 mM DTT). The release of fluorescent 7-amino-4-methylcoumarin 
in the presence of the indicated concentrations of glyburide, glipizide, or 
the caspase-1 inhibitor Ac-YVAD-cmk was measured for 30 min at 1-min 
intervals by fluorometry (excitation at 360 nm and emission at 480 nm) on 
a Cytofluor (PerSeptive Biosystems), and the maximal rate of increase in 
fluorescence was calculated (F/min).
ATPase assay
ATP hydrolysis was measured by visualizing the conversion of -[
32P]ATP to 
-[
32P]ADP using TLC. A total of 5 µl purified Cryopyrin-Flag was incubated 
with 0.1 µM -[
32P]ATP (3,000 Ci/mmol; PerkinElmer) in a total volume of 
20 µl reaction buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM 
MgCl2, 1 mM DTT, 1 mM EDTA, and EDTA-free Complete protease inhibi-
tor cocktail tablets) containing 100 µM glyburide, compound G1, glipi-
zide, or vehicle control (DMSO) for 2 h. The reaction was quenched by 
adding an equal volume of TLC development solvent (1 M formic acid and 
0.5 M LiCl). A total of 2 µl reaction mixture was spotted on a polyethylene-
imine cellulose TLC plate and developed with 1 M formic acid with 0.5 M 
LiCl in a TLC chamber. The TLC plate was exposed to x-ray film or used for 
quantification with a phosphoimager (Typhoon Trio; GE Healthcare).
Online supplemental material
Fig. S1 shows that LPS+ATP-induced caspase-1 activation and macrophage 
death are glyburide sensitive and, unlike LPS+nigericin, require the P2X7 
receptor. Fig. S2 shows that LPS+H-LL-OMe– and LPS+silica-induced cas-
pase-1 activation and IL-1 secretion require Cryopyrin and TLR4 but not 
the P2X7 receptor. Fig. S3 shows inhibition of caspase-1 activation by 
DIDS, immunopurification of recombinant Cryopyrin-Flag, and IL-1 secre-
tion from FCAS monocytes. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200903124/DC1.
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were approved by the Institutional Animal Care and Use Committee at 
Genentech. BMDMs were prepared as described previously (Lamkanfi et al., 
2007). In brief, BMDMs were isolated from femurs of 6–12-wk-old mice and 
were cultured in Iscove’s modified Dulbecco’s medium containing 10% heat-
inactivated FBS, 20% L cell–conditioned medium, 100 U/ml penicillin, and 
100 mg/ml streptomycin at 37°C in a humidified atmosphere containing 5% 
CO2. After 5–7 d of incubation, cells were collected and plated in 6- or 24-
well plates in Iscove’s modified Dulbecco’s medium containing 10% heat- 
inactivated FBS and 100 mg/ml thymidine and antibiotics. Macrophages 
were cultured for an additional 24 h before use.
LPS-induced endotoxemia
8-wk-old male C57BL/6 mice (Charles River) were maintained in micro-
isolator cages and received food and water ad libitum according to the 
American Association of Laboratory Animal Care guidelines. Mice were ran-
domly divided into two groups (n = 10/group). The mice were injected   
intraperitoneally bid daily with 500 mg/kg glyburide or the formulation vehicle 
(DMSO/10% HP-b-CD [2.5:97.5]) in 360 µl PBS. 4 h after the first dosing, 
endotoxic shock was induced by intraperitoneal injection of 18 mg/kg LPS 
(Escherichia coli O111:B4; Sigma-Aldrich). Mice were monitored hourly 
for survival up to 36 h. Differences in group survival were analyzed with 
the Kaplan–Meier test. P < 0.05 was considered statistically significant.
Patients
The University of California San Diego Human Research Protection Pro-
gram Committee approved this study, and informed consent was obtained 
from all subjects. Three related patients with FCAS (L353P mutation) and 
five normal controls were included. The FCAS patients had a classical clini-
cal  presentation,  met  diagnostic  criteria,  and  were  being  treated  with 
Rilonacept, an IL-1 inhibitor approved by the Food and Drug Administra-
tion, but held their dose for >2 wk before the experiment.
Preparation of human adherent monocytes
Venous blood was drawn into EDTA/Vacutainer tubes (BD) early in the 
morning when FCAS patients are generally least symptomatic. PBMC frac-
tions were collected and resuspended in serum-free media and transferred 
to 24-well plates at a concentration of 1 × 10
6/ml. Cells were incubated 
for 4 h at 37°C, and nonadherent cells were removed leaving adherent 
monocytes as previously described (Rosengren et al., 2007).
Bacteria, ligands, and inhibitors
S. enterica serovar typhimurium strain SL1344 was provided by D. Monack 
(Stanford University, Palo Alto, CA). Single colonies were inoculated into 
3 ml of brain-heart infusion medium and grown overnight at 30°C with 
shaking. Anthrax lethal factor and protective antigen (List Biological Labo-
ratories) were used at 10 µg/ml. Ultrapure LPS, lipid A, lipoteichoic acid, 
peptidoglycan, and Pam3-CSK4 (InvivoGen) were used at 10 µg/ml. ATP 
(Roche) was used at 5 mM, and nigericin (Sigma-Aldrich) was used at a 
final concentration of 20 µM. Glyburide, glipizide, and calmidazolium 
were obtained from Sigma-Aldrich and used at the indicated concentra-
tions. Compounds G1–G4 were purchased from Ryan Scientific. DOTAP 
was obtained from Roche and used according to the manufacturer’s in-
structions. Silicia (Min-U-Sil 5) was provided by US Silica, and H-LL-OMe 
was purchased from Chem-Impex International. Infection and stimulation of 
BMDMs were performed as described in Figs. 1–5.
Microscopy
Bright-field and fluorescence microscopy were performed in culture media   
at room temperature under a long-distance Plan Neofluar 20×/0.4 Ph2 
Korr objective (Carl Zeiss, Inc.) on a microscope (Axiovert 200M; Carl Zeiss, 
Inc.) equipped with a charge-coupled device digital camera (Axiocam; 
Carl Zeiss, Inc.) and AxioVision software (Rel.4.6; Carl Zeiss, Inc.). For 
dye uptake assays, 2 µM YoPro-1 (Invitrogen) was present 10 min before 
macrophages were stimulated with ATP for 5 min. Fluorescence signals in 
digital black and white fluorographs were artificially colored green with 
phosphoimaging. Data represent the mean ± SD of triplicate samples from one out of three independent experiments. (F) Adherent monocytes from FCAS 
patients (n = 3) were stimulated with 100 ng/ml LPS (4 h) and treated with 5 mM ATP (30 min) in the presence of vehicle controls or 100 µM compound 
G1 or glipizide before IL-1 levels in culture supernatants were determined. Data represent the mean ± SD of triplicate samples. (G) Adherent monocytes 
from FCAS patients (n = 3) were cultured at 32°C for 12 h in the presence of vehicle controls or 100 µM compound G1 or glipizide. IL-1 levels were 
determined in culture supernatants. Data represent the mean ± SD of triplicate samples. (H) Protection against LPS-induced lethality in C57BL/6 mice (n = 10) 
injected intraperitoneally bid daily with 500 mg/kg glyburide or formulation vehicle. Results are representative of two independent experiments.
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